Get the Stockscreener App
0.3845
1.18%
0.0045
After Hours:
.39
0.0055
+1.43%
Transcode Therapeutics Inc stock is traded at $0.3845, with a volume of 267.20K.
It is up +1.18% in the last 24 hours and down -36.97% over the past month.
TransCode Therapeutics Inc is a clinical-stage oncology company focused on treating metastatic disease. It is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode is developing a portfolio of first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.
See More
Previous Close:
$0.38
Open:
$0.3907
24h Volume:
267.20K
Relative Volume:
0.17
Market Cap:
$6.64M
Revenue:
-
Net Income/Loss:
$-19.59M
P/E Ratio:
-0.0158
EPS:
-24.29
Net Cash Flow:
$-16.49M
1W Performance:
+13.19%
1M Performance:
-36.97%
6M Performance:
-73.30%
1Y Performance:
-96.07%
1-Day Range:
$0.36
$0.3907
1-Week Range:
$0.32
$0.3907
52-Week Range:
$0.216
$18.66
Transcode Therapeutics Inc Stock (RNAZ) Company Profile
Name
Transcode Therapeutics Inc
Sector
Industry
Phone
857-301-6857
Address
6 LIBERTY SQUARE, BOSTON
Compare RNAZ with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| RNAZ | 0.3845 | 6.64M | 0 | -19.59M | -16.49M | -24.29 |
| VRTX | 450.97 | 116.14B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 738.00 | 81.10B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 605.92 | 36.23B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 244.89 | 31.59B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 113.13 | 27.12B | 3.30B | -501.07M | 1.03B | 11.54 |
Transcode Therapeutics Inc Stock (RNAZ) Latest News
Craig Hallum Downgrades Sow Good (NASDAQ:SOWG) to Hold - Defense World
TransCode Therapeutics (NASDAQ:RNAZ) Receives Buy Rating from HC Wainwright - Defense World
The Goldman Sachs Group Boosts Tarsus Pharmaceuticals (NASDAQ:TARS) Price Target to $41.00 - Defense World
TScan Therapeutics (NASDAQ:TCRX) Earns “Buy” Rating from HC Wainwright - Defense World
Sow Good (NASDAQ:SOWG) Lowered to Neutral Rating by Roth Mkm - Defense World
Spero Therapeutics’ (SPRO) “Overweight” Rating Reiterated at Cantor Fitzgerald - Defense World
TransCode Therapeutics Inc (RNAZ) Quarterly 10-Q Report - Quartzy
Transcode Therapeutics Reports Increased Losses Amid Funding Challenges - TipRanks
Transcode Therapeutics sends open letter to shareholders - TipRanks
TransCode Therapeutics Open Letter to Shareholders - The Manila Times
TransCode (RNAZ) Faces Delisting Risk, Seeks Shareholder Approval for Reverse Split | RNAZ Stock News - StockTitan
TransCode Therapeutics maintains Nasdaq listing with conditions - Investing.com
TransCode Therapeutics Announces Nasdaq Extension to Regain Compliance - The Manila Times
TransCode Therapeutics maintains Nasdaq listing with conditions By Investing.com - Investing.com UK
TransCode (RNAZ) Maintains Nasdaq Listing Despite Reprimand Over Compliance Issues | RNAZ Stock News - StockTitan
TransCode advances to phase 1 cancer trial's next stage - Investing.com
ORIC® Pharmaceuticals Presents Data Further Supporting Potential Best-In-Class Profile of ORIC-114 to Treat EGFR Exon 20 Insertions and Other Atypical Mutations at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics - The Manila Times
TransCode Therapeutics Announces Safety Review Committee Approval of Second Cohort Opening in Phase 1 TTX-MC138 Clinical Trial Following Favorable Review of Cohort 1 Safety Data - StockTitan
Form PRE 14A Transcode Therapeutics, For: Oct 15 - StreetInsider.com
TransCode Therapeutics Inc (RNAZ) is a good investment, but the stock may be undervalued - US Post News
Tevogen Bio (Nasdaq: TVGN) Stock Recovers After Major Updates - DRP Journal
TransCode Therapeutics Inc. (NASDAQ: RNAZ) Stock Sees Bullish Move: But Why? - DRP Journal
BloomZ Inc. (NASDAQ: BLMZ) Stock Rockets On a New Contract - DRP Journal
TransCode Therapeutics Inc (NASDAQ:RNAZ) stock crossing the finish line today - US Post News
TransCode Therapeutics Completes Initial Dosing of First Cohort in Phase 1 Clinical Trial with TTX-MC138, a - EIN News
There is no doubt that TransCode Therapeutics Inc (RNAZ) ticks all the boxes. - SETE News
TransCode Therapeutics Completes Initial Dosing of First Cohort in Phase 1 Clinical Trial with TTX-MC138, a microRNA-Targeted Technology - The Manila Times
RNAZ’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - The InvestChronicle
TransCode Therapeutics Inc (RNAZ)’s stock chart: A technical perspective - US Post News
Halozyme (HALO) Stock Surges Amid Positive Earnings and Analyst Ratings - GuruFocus.com
TransCode Therapeutics Inc’s Market Journey: Closing Weak at 0.49, Down -15.04 - The Dwinnex
U.S. shares mixed at close of trade; Dow Jones Industrial Average down 0.21% - MSN
Riding the Waves: A Guide to Investing in RNAZ Stock - The InvestChronicle
Transcode Therapeutics faces potential Nasdaq delisting - Investing.com
TransCode Therapeutics Inc (RNAZ): Worth A Small Bite At $0.62 - Stocks Register
TransCode Therapeutics Begins Dosing Patients in Phase 1 Trial for Metastatic Cancer Therapy - Proactive Investors USA
U.S. shares mixed at close of trade; Dow Jones Industrial Average down 0.70% - MSN
TransCode Therapeutics Inc (RNAZ) expanding its growth trajectory ahead - SETE News
Gaining Ground: TransCode Therapeutics Inc (RNAZ) Closes Higher at 0.42, Up 35.75 - The Dwinnex
TransCode Therapeutics Inc (RNAZ) presents a great opportunity, but the stock is slightly undervalued - US Post News
Ratio Review: Analyzing TransCode Therapeutics Inc (RNAZ)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Taking the lead: TransCode Therapeutics Inc (RNAZ) - SETE News
Recent Insider Activity Could Benefit Ocean Power Technologies (OPTT) - Knox Daily
W.R. Berkley Corp. [WRB] Investment Appeal on the Rise - Knox Daily
TransCode begins Phase 1 trial of metastatic cancer treatment By Investing.com - Investing.com Canada
RNAZ’s Financial Health: Exploring TransCode Therapeutics Inc’s Debt-to-Equity Ratio of 1.79 - The InvestChronicle
RNAZ’s price-to-sales ratio: A comparative analysis with its peers - US Post News
TransCode begins Phase 1 trial of metastatic cancer treatment - Investing.com
TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate - StockTitan
TransCode reports progress in metastatic breast cancer treatment By Investing.com - Investing.com Australia
Transcode Therapeutics announces publication of study on TTX-MC138 - TipRanks
Transcode Therapeutics Inc Stock (RNAZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.89%
2.08%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):